SEC Form 4 · accession 0001553878-17-000004
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip A Sharp
Director
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 18, 2017 | M | 15,000 | $15.91 | A | 155,795 | D | |
| Common StockF2 | Jan 18, 2017 | S | 8,800 | $37.57 | D | 146,995 | D | |
| Common StockF3 | Jan 18, 2017 | S | 6,200 | $38.20 | D | 140,795 | D | |
| Common StockF4 | holding | — | — | — | 126,104 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $15.91 | Jan 18, 2017 | M | 15,000 | D | Jun 1, 2008 | Jun 1, 2017 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.
- F2Sale prices ranged from $37.07 to $38.06
- F3Sale prices ranged from $38.09 to $38.50
- F4The 126,104 shares reported as indirectly owned by trust include: (i) 94,838 shares in the Phillip A. Sharp 2009 Grantor Annuity Trust No. 3, and (ii) 31,266 shares in the Phillip A. Sharp 2008 Grantor Annuity Trust No. 2 (which include shares distributed from the 2010 Trust).